November 1, 2019 / 6:42 AM / 12 days ago

Novartis arthritis drug fails to prove it is significantly better than rival

ZURICH, Nov 1 (Reuters) - A clinical trial of Novartis’s Cosentyx drug has failed to prove it is significantly better than a rival treatment for a type of arthritis, the Swiss company said on Friday.

Novartis said Cosentyx, when used to treat active psoriatic arthritis, “narrowly missed statistical significance for superiority” versus Humira, a drug made by AbbVie.

“While Cosentyx narrowly missed statistical significance for superiority.... it showed numerically higher results versus Humira,” Novartis said following the results of a head-to-head trial.

Psoriatic arthritis, an inflammatory disease affecting the joints, is a condition which affects around 50 million people worldwide.

This week U.S. regulators halted a trial of Novartis’s Zolgensma treatment after an animal study raised safety concerns. (Reporting by John Revill; Editing by Michael Shields)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below